RIPK1 and acute kidney injury: In short, artesunate inhibits the activation of M1 macrophages and the RIPK1/RIPK3/MLKL signalling pathway by down‐regulating the expression of Mincle, thus reducing the inflammatory response and necroptosis, and further improving the renal injury of AKI.